Bristol needs to get fresh
Move over Amgen – Bristol Myers Squibb now looks like the big biopharma group most in need of revitalisation.
Thought CETP inhibition was dead? Think again
New Amsterdam wants to prove that the ill-fated mechanism has a role in cardiovascular disease – and this time it’s all about the bad cholesterol.
AACR 2022 – Novartis’s late Kras challenge to Amgen
Targeting Shp2 has disappointed, but Novartis shows that it might still make an impression in directly hitting Kras.
Despite slow progress, Boehringer keeps faith in oncology
The group highlights its ambitions in cancer again, but is at least two years away from launching a new product.
How Covid failed to derail the FDA
Average US review times match absolute approval numbers in remaining unaffected by the Covid pandemic.
